newsfilter
← Latest News
ACCESS Newswire·

Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress

PTGX
  • Protagonist Therapeutics announced four rusfertide abstracts for the 2026 EHA Congress in Stockholm from June 11-14, 2026.
  • Presentations cover data from the Phase 3 VERIFY study & long-term results from Phase 2 REVIVE & THRIVE open-label extension studies.
  • Abstracts analyze efficacy, safety, cytoreductive therapy use, thromboembolic events, disease progression, & patient-reported outcomes in phlebotomy-dependent PV patients.
  • All four presentations occur during Poster Session 1 on Friday, June 12, 2026, between 18:45-19:45 CEST.
  • The specific poster numbers are PF892, PF891, PF890, & PF898.
  • Protagonist's ICOTYDE is approved in the U.S. for psoriasis via a license with Janssen Biotech.
  • An NDA for rusfertide is under priority FDA review as a hepcidin mimetic co-developed with Takeda Pharmaceuticals.
  • Protagonist holds an option to co-commercialize rusfertide in the U.S. under a 50/50 profit & loss share structure.
  • The company maintains preclinical programs targeting IL-17, obesity, hepcidin, IL-4, & amylin.